Skip to main content

Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].

Publication ,  Journal Article
Morris, MJ; Mota, JM; Lacuna, K; Hilden, P; Gleave, M; Carducci, MA; Saad, F; Cohn, ED; Filipenko, J; Heller, G; Shore, N; Armstrong, AJ; Scher, HI
Published in: Eur Urol Oncol
October 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol Oncol

DOI

EISSN

2588-9311

Publication Date

October 2022

Volume

5

Issue

5

Start / End Page

603

Location

Netherlands

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morris, M. J., Mota, J. M., Lacuna, K., Hilden, P., Gleave, M., Carducci, M. A., … Scher, H. I. (2022). Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. Eur Urol Oncol, 5(5), 603. https://doi.org/10.1016/j.euo.2022.08.001
Morris, Michael J., Jose Mauricio Mota, Kristine Lacuna, Patrick Hilden, Martin Gleave, Michael A. Carducci, Fred Saad, et al. “Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].Eur Urol Oncol 5, no. 5 (October 2022): 603. https://doi.org/10.1016/j.euo.2022.08.001.
Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. Eur Urol Oncol. 2022 Oct;5(5):603.

Published In

Eur Urol Oncol

DOI

EISSN

2588-9311

Publication Date

October 2022

Volume

5

Issue

5

Start / End Page

603

Location

Netherlands

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences